Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study.

Axel De GreefPierre-Dominique GhislainAudrey BulinckxAlison CosterCéline de HalleuxThomas DamsinMarie-Claude JacobsErwin SuysSamer ZoghaibMarie Baeck

Published in: Clinical drug investigation (2023)

Tralokinumab is an effective first-line biotherapy for severe AD. However, therapeutic response may be progressive. Safety data were reassuring. Atopic dermatitis flares or reactions at the injection site may lead to discontinuation of treatment. A history of conjunctivitis on dupilumab is not a contraindication to the initiation of tralokinumab.

Keyphrases

atopic dermatitis
early onset
multiple sclerosis
big data
combination therapy
electronic health record
machine learning
smoking cessation